Molecular Expression Differences in Specific Blood Mononuclear Cell‐Types Identify Patients With AL Amyloidosis
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von David Kaplan und 11 weiteren Autor:innen. Beteiligte Einrichtung: CellPrint Biotechnology, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Leukocytes, Mononuclear. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson.
Abstract (Originalsprache)
The diagnosis of AL amyloidosis is often challenging due to its systemic nature and heterogeneous clinical presentation. Current serological biomarkers for diagnosis and monitoring are not optimal. We have considered the possibility that mononuclear cell‐type specific molecular expression can be used to develop blood‐based biomarkers to diagnose and monitor patients with AL amyloidosis. Peripheral blood monocytes and CD4 + T cells from patients with documented AL amyloidosis or myeloma without amyloidosis were assessed by enhanced flow cytometric analysis for expression levels of 20 analytes chosen for the possibility that their expression levels may lead to diagnostic assays and biomarkers. We found definitive expression level differences for brain‐derived neurotrophin factor (BDNF), calmodulin, and phospho‐TBK1 in CD4 + T cells and for phospho‐GSK3β in monocytes. Logistic regression and ROC analysis showed that BDNF in CD4 + T cells and heme oxygenase 1 in monocytes significantly distinguished between patients with myeloma versus patients with AL amyloidosis (AUC = 0.75). Additionally, we discovered remarkable differences in intermolecular associations between the samples from the two patient groups, suggesting the involvement of specific pathogenetic pathways. Our results demonstrate that mononuclear cell‐type specific molecular expression may be useful for developing a diagnostic assay and biomarkers for patients with AL amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CellPrint Biotechnology, Cleveland, Ohio, USA.
- Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
- Amyloidosis Center, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID-Profile: David Kaplan, Faiz Anwer, Hillard M Lazarus, Jack Khouri
Förderung
- Johnson and Johnson
Zitieren
APA
Kaplan, D., Christian, E., Valent, J., Anwer, F., Mazzoni, S., Samaras, C., Williams, L., Nakashima, M., Raza, S., Hanna, M., Lazarus, H. M., & Khouri, J. (2025). Molecular Expression Differences in Specific Blood Mononuclear Cell‐Types Identify Patients With AL Amyloidosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70850
Vancouver
Kaplan D, Christian E, Valent J, Anwer F, Mazzoni S, Samaras C, et al. Molecular Expression Differences in Specific Blood Mononuclear Cell‐Types Identify Patients With AL Amyloidosis. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70850
BibTeX
@article{Kaplan2025,
author = {Kaplan, David and Christian, Eric and Valent, Jason and Anwer, Faiz and Mazzoni, Sandra and Samaras, Christy and Williams, Louis and Nakashima, Megan and Raza, Shahzad and Hanna, Mazen and Lazarus, Hillard M and Khouri, Jack},
title = {Molecular Expression Differences in Specific Blood Mononuclear Cell‐Types Identify Patients With AL Amyloidosis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70850}
}
EUVIMED